Deal Watch: Pfizer/AstraZeneca Lead Pack Of Takeover Efforts
Executive Summary
Pfizer’s new, increased offer for AstraZeneca on May 2 was rejected swiftly by the U.K.’s second-largest pharmaceutical company. But other companies’ acquisitive strategies have been more successful this week, with Forest announcing plans to acquire Furiex, Bristol buying out one-asset biotech iPierian, and Endo nabbing the privately owned Mexican specialty company, Somar.
You may also be interested in...
Merck Not Feeling Mega-Merger Mania Even As Pharma Sales Decline
Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.
Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate
With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).